BioSpace News Archive

The report developed by Transparency Market Research on the global capnography equipment market expects to reach an overall market cap of US$615.6 mn by the fall of 2020.

Clopidogrel has remained, ever since its first approval in 1997, the antiplatelet therapy of choice among physicians for the treatment of patients with conditions such as acute coronary syndrome or percutaneous coronary intervention.

Reported net sales of $491 million, down 51.4% vs. prior year, impacted by COVID-19. Organic sales declined 49.9% versus prior year

Conformal Medical, Inc., a medical device company focused on reducing stroke in patients with atrial fibrillation, announced it has secured $85 million in Series C financing.

Curated Menu of Off-the-Shelf RNAscope Probes Provide Molecularly-Guided Region of Interest Selection for Use with the New NGS-Enabled Cancer Transcriptome Atlas

BiomX Inc. (NYSE: PHGE), a clinical-stage company developing both natural and engineered phage therapies that target specific pathogenic bacteria, today announced that the Company will host a conference call and live audio webcast on Thursday, Aug. 13, 2020, at 8:00 a.m. EDT, to report second quarter 2020 financial results and provide a corporate update. The conference call dial-in numbers are 1-877-407-0724 (U.S.), 1-

Orthofix Medical Inc. reported its financial results for the second quarter ended June 30, 2020. Net sales were $73.1 million, earnings per share was and adjusted EPS was.

Abiomed, Inc. (NASDAQ: ABMD), a leading provider of breakthrough heart support technologies today reported first quarter fiscal 2021 revenue of $164.9 million compared to revenue of $207.7 million for the same period of fiscal 2020 despite a negative impact from the COVID-19 pandemic. The company delivered sequential revenue and patient growth each month within the quarter, wi

– Grew LINZESS ® (Iinaclotide) total prescription demand by 9% year-over-year; new-to-brand prescription demand grew >15% in June 2020 compared to March 2020 – – Made important updates designed to strengthen IW-3718 Phase III program; FDA indicated that long-term safety study for IW-3718 is not required for an NDA submission – – Reinstating full year 2020 total revenue and LINZESS net sales growth guidance; reiterating adjusted EBITDA gu

TAE Life Sciences, a biological-targeting radiation therapy company developing next-generation boron neutron capture therapy solutions, announced that Bruce Bauer, Chief Executive Officer, will present a corporate overview at the Summer 2020 Private Company Showcase, hosted by Solebury Trout, on August 10, 2020.